NRx Pharmaceuticals Shares Insights at Investment Conference
Wilmington, Delaware — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a dedicated clinical-stage biopharmaceutical company focused on groundbreaking treatments, is set to participate in an engaging fireside chat at the highly anticipated H.C. Wainwright's 27th Annual Global Investment Conference.
Event Details and Participation
Scheduled for a Monday session, this discussion is slated to begin at 4:30 PM ET, with Jonathan Javitt, M.D., M.P.H., the esteemed Chairman and CEO of NRx Pharmaceuticals, leading the dialogue. This event provides a pivotal platform for the company's leadership to articulate its vision and strategic objectives to potential investors.
Access the Event Webcast
A webcast featuring the fireside chat will be accessible on NRx Pharmaceuticals' official site in the Investors section. Those unable to attend the live event will still have the opportunity to view the session as it will be archived for two hours after the talk, remaining available for a full 30 days.
One-on-One Investor Interactions
In addition to the main event, NRx Pharmaceuticals will engage in various one-on-one meetings throughout the conference. They encourage investors interested in connecting with their management team to reach out through their H.C. Wainwright representatives or directly with Brian Korb at astr partners.
Innovative Therapies from NRx Pharmaceuticals
NRx Pharmaceuticals is recognized for its innovative therapeutic targets, particularly those addressing complex central nervous system disorders. The company's focus on suicidal depression, chronic pain, and PTSD is showcased through their NMDA platform.
Key Developments and Designations
NRx is advancing two promising therapies: NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral formulation combining D-cycloserine with lurasidone. Both candidates have achieved important designations, including Fast Track for NRX-100 and Breakthrough Therapy for NRX-101 in treating bipolar depression.
About NRx Pharmaceuticals
As a clinical-stage biopharmaceutical leader, NRx Pharmaceuticals aims to innovate therapeutic solutions that can profoundly impact patients' lives. The company actively pursues regulatory milestones, recently initiating an Abbreviated New Drug Application (ANDA) and a New Drug Application for NRX-100.
Introduction to HOPE Therapeutics
In addition to its innovative pharma work, NRx Pharmaceuticals oversees HOPE Therapeutics, Inc., a healthcare delivery network focusing on interventional psychiatry solutions. This subsidiary is committed to creating a robust network of clinics delivering essential therapies, including ketamine and transcranial magnetic stimulation (TMS).
Contact Information for Inquiries
For more in-depth communication, Matthew Duffy serves as Co-CEO of HOPE Therapeutics and can be reached via email. For representation at the investment conference, Brian Korb remains available for inquiries and further information.
Frequently Asked Questions
What is the purpose of NRx Pharmaceuticals’ participation in the conference?
The company aims to connect with investors, sharing its strategic vision and advancements in mental health therapies.
How can individuals access the conference webcast?
The webcast will be available on NRx Pharmaceuticals' official Investors page, offering an archive for later viewing.
What innovations is NRx Pharmaceuticals focusing on?
NRx Pharmaceuticals is concentrating on developing treatments for central nervous system disorders, particularly suicidal depression and PTSD.
Who leads the fireside chat for NRx Pharmaceuticals?
The chat will be led by Jonathan Javitt, M.D., M.P.H., Chairman and CEO of NRx Pharmaceuticals.
What are the key therapies being developed by NRx Pharmaceuticals?
The company is working on NRX-100 and NRX-101, innovative treatments aimed at addressing severe mental health issues.
